2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Hall C
Treatment Considerations, Combination Therapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Animal Model
PAPER

227 ASXL1 mutations sensitize acute myeloid leukemia to menin inhibition and synergize with XPO1 blockade

Christopher P Mill, PhD, Caroline Hsu, N/A2, Hanxi Hou, N/A3, Koji Sasaki, MD, PhD4, Sanam Loghavi, MD5, Ghayas C. Issa, MD6, Courtney DiNardo, MD, MSCE7, Naval Daver, MD8, Xiaoping Su, PhD9, Guillermo Garcia-Manero, MD10, Jayastu Senapati, MBBS, MD, DM11, Warren Fiskus, PhD12
1 UT MD Anderson Cancer Center, Houston, United States
2 Vanderbilt University, Nashville, United States
3 UT MD Anderson Cancer Center, Houston, United States
4 Institute of Science Tokyo, Tokyo, Japan
5 UT MD Anderson Cancer Center, Houston, United States
6 UT MD Anderson Cancer Center, Houston, United States
7 UT MD Anderson Cancer Center, Houston, United States
8 UT MD Anderson Cancer Center, Houston, United States
9 UT MD Anderson Cancer Center, Houston, United States
10 UT MD Anderson Cancer Center, Houston, United States
11 UT MD Anderson Cancer Center, Houston, United States
12 UT MD Anderson Cancer Center, Houston, United States

Background: ASXL1 is among the most frequently mutated epigenetic regulators in acute myeloid leukemia (AML), occurring in 5–20% of patients and conferring poor clinical outcomes. Truncating ASXL1 mutations stabilize the ASXL1–BAP1 polycomb repressive deubiquitinase (PR-DUB) complex, resulting in global loss of H2AK119 ubiquitination (Ub) and transcriptional activation, including increased expression of HOXA9 and MEIS1. Because these genes are key downstream targets of the KMT2A–Menin transcriptional complex, we hypothesized that ASXL1-mutant AML exhibits increased dependence on Menin signaling and is therefore particularly sensitive to Menin inhibition.

Menin inhibitors have demonstrated significant clinical activity in AML harboring KMT2A rearrangements, NUP98 rearrangements, and NPM1 mutations, leading to the recent approval of two Menin inhibitors for patients with relapsed/refractory NPM1-mutant and/or KMT2A-rearranged AML. As monotherapy, both agents achieve complete remission (CR) or CR with partial hematologic recovery (CRh) rates of approximately 20% with median response durations of 4–6 months. More recently, the SAVE study demonstrated that combining revumenib (SNDX-5613) with ASTX727 and venetoclax increased CR/CRh rates to approximately 60% and extended the median duration of response to 10.5 months. These findings suggest that Menin inhibitor-based combination therapies may further improve outcomes in ASXL1-mutant AML.

Methods: To test this hypothesis, we generated paired CRISPR/Cas9 knock-in (KI) models harboring the clinically relevant ASXL1 Y591* mutation in OCI-AML2 and OCI-AML3 cells, both of which express ASXL1 wild-type (wt). ASXL1-mutant KI cells demonstrated increased ASXL1 and BAP1 protein expression with reduced H2AK119Ub, confirming activation of the PR-DUB complex. These paired isogenic models were used to evaluate the activity of the Menin inhibitors revumenib precursor (VTP-50469) and ziftomenib (KO-539), alone and in combination with azacitidine or the XPO1/CRM1 inhibitor eltanexor (KPT-8602).

Results: Introduction of mutant ASXL1 significantly enhanced sensitivity to both Menin inhibitors in the intrinsically responsive OCI-AML3 (NPM1-mutant; e.g., ASXL1-wt LD50 98.9 nM vs. ASXL1-mut 25.0 nM to VTP-50469) model and converted the relatively resistant OCI-AML2 model into a Menin inhibitor-sensitive phenotype (e.g., ASXL1-wt LD50 > 1,000 nM vs. ASXL1-mut 67.5 nM to VTP-50469). Menin inhibition consistently suppressed expression of canonical KMT2A target genes, including PBX3, MEIS1, CDK6, and FLT3, while concomitantly increasing expression of the differentiation-associated genes CDKN1A (p21) and ITGAM (CD11b). Corresponding reductions in MEIS1, CDK6, FLT3, and BCL2 protein expression were also observed. These findings demonstrate that mutant ASXL1 promotes dependence on Menin-regulated transcriptional programs and establishes Menin inhibitor sensitivity across genetically distinct AML models.

Given that resistance and relapse remain major limitations of Menin inhibitor therapy, we next evaluated rational combination strategies. Combination treatment with azacitidine produced synergistic lethality (ZIP synergy score = 5.99) and enhanced myeloid differentiation (% CD11b-positive: control = 0.3%, VTP-50469 (VTP) = 10.4%, azacitidine (aza) = 0.3%, VTP + aza = 32.7%) in the OCI-AML2 ASXL1-mutant model, but not in OCI-AML3 ASXL1-mut KI cells, suggesting that additional genomic or epigenetic factors influence HMA responsiveness. In contrast, combination treatment with eltanexor demonstrated robust and reproducible synergy in both ASXL1-mutant models (ZIP synergy score OCI-AML2 = 14.07; OCI-AML3 = 22.28), producing substantially greater leukemic cell killing than either agent alone.

Conclusions: Using two independent paired isogenic AML models, we demonstrate for the first time that a mutation in ASXL1 is sufficient to confer increased sensitivity to Menin inhibition. Furthermore, XPO1 inhibition represents a robust combination strategy across distinct ASXL1-mutant AML models. These findings identify ASXL1 mutation as a potential predictive biomarker of Menin inhibitor response and provide strong preclinical rationale for expanding clinical evaluation of Menin inhibitor-based therapies, particularly in combination with XPO1 inhibition, in patients with ASXL1-mutant AML.

Christopher P Mill, PhD: No relevant conflicts of interest to declare.